drugset / Trial / NCT00954642
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | VESENCUMAB | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.